Navigation Links
Emageon Files Quarterly Report
Date:8/11/2008

BIRMINGHAM, Ala., Aug. 11 /PRNewswire-FirstCall/ -- Emageon Inc. (Nasdaq: EMAG) earlier today filed with the Securities and Exchange Commission its quarterly report on Form 10-Q for the second quarter ended June 30, 2008. Investors are encouraged to review this document carefully, including the discussion of additional risks and uncertainties to which the Company is subject and the information regarding a charge for impairment of certain intangible assets.

As previously announced, the Strategic Alternatives Committee of the Company's Board of Directors is pursuing a broad mandate to consider all strategic alternatives for the Company, including a sale of the Company. This process remains ongoing at this time. Given the ongoing investigation of strategic alternatives, the Company is at this time withdrawing all previously issued financial guidance for 2008, which guidance should no longer be relied upon, and will not provide financial guidance for the remainder of 2008.

Forward Looking Statements

This press release contains forward-looking statements about Emageon that represent the Company's current views with respect to, among other things, future events and financial performance. Any forward-looking statements contained in this press release are based on Emageon's historical performance and on current plans, beliefs and expectations. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various risks, uncertainties and other factors beyond its control. These risks, uncertainties and other factors include, among others, risks associated with its ongoing investigation of strategic alternatives, the risk that it may not compete successfully against larger competitors, risks associated with the cyclical nature of its industry and changes in economic conditions in general, risks associated with its history of operating losses, risks associated with changes in its primary market for PACS radiology systems and the decline in PACS radiology system sales orders, risks associated with fluctuations in its quarterly operating results, risks associated with the decline in the market price of its common stock, the risk of loss of its senior executive management, risk associated with expansion of its market and selling efforts into new product segments, the risk that its target markets do not develop as expected, the risk of failure to raise additional capital on acceptable terms, risks associated with its reliance on continuing relationships with large customers, the risk of significant product errors or product failures, the risk of its reliance on reseller arrangements for important components of its solution, the risk that it may not respond effectively to changes in its industry, the risk of its customers' reliance on third party reimbursements, and the risk of the potential impact on its business of Food & Drug Administration (FDA) regulations and other applicable health care regulations. Additional information concerning these and other factors that could affect Emageon's financial and operating results may be found under the heading "Risk Factors" and elsewhere in the Company's Form 10- K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on March 17, 2008, and the Company's Form 10-Q for the

quarter ended June 30, 2008, which was filed with the Securities and Exchange Commission on August 11, 2008.

Emageon undertakes no obligation to update these forward-looking statements or other information provided in this press release except as may be required by law.

About Emageon Inc.

Emageon provides information technology systems for hospitals, healthcare networks and imaging facilities. Its enterprise family of solutions includes RadSuite(TM), HeartSuite(TM) and other specialty suites. All Emageon solutions are built on a unified Enterprise Content Management system offering advanced visualization and infrastructure tools for the clinical analysis and management of digital medical images, reports and associated clinical content. Emageon's standards-based solutions are designed to help customers enhance patient care, automate workflow, lower costs, improve productivity and provide better service to physicians. For more information, please visit http://www.emageon.com.


'/>"/>
SOURCE Emageon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Emageon Reports Third Quarter 2007 Financial Results
2. Emageon Names Chris E. Perkins as Chief Operating Officer
3. Emageon to Present at the 26th Annual JPMorgan Healthcare Conference
4. Foundation Radiology Group Formalizes Strategic Partnership with Emageon to Provide Advanced Imaging Software to Facilitate Industry-Leading Turnaround and Patient Care Response Times
5. Emageon Inc. to Host Fourth Quarter 2007 Financial Results Conference Call February 21, 2008
6. Emageon Reports Fourth Quarter and 2007 Financial Results
7. Emageon to Present at Raymond James 29th Annual Institutional Investors Conference
8. Emageon Receives Best in KLAS Cardiology PACS Award
9. Emageon Inc. to Host First Quarter 2008 Financial Results Conference Call May 12, 2008
10. Emageon to Present at the Jefferies 2nd Annual Healthcare Conference
11. Emageon Selects Jefferies & Company and SunTrust Robinson Humphrey as Advisors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively new ... is not known to have significant interactions with antiretroviral therapy (ART). Among ... levels and dampen inflammation in the bloodstream. , While lowering cholesterol and dampening ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. ... has not found any of them to be very practical. She wanted to write ... easily make changes in their health. It prompted her in writing “ A Clear ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “The Saint with ... with Trin, and Omega Station” is the creation of published author, Chris Jackson. ... Metroplex where he works in the Dallas Independent School District teaching English. He is ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a pre-clinical stage ... the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna ... advances towards regulatory and clinical phases. , "This is another important step for ...
(Date:4/22/2017)... Carolina (PRWEB) , ... April 22, 2017 , ... Ecommerce ... the United States estimated to be $394.9 billion. The consequences of rapid innovation ... inevitably demolishes) the limits of technology, it is every business and individual’s job to ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... April 19, 2017 ... immune response in pets such as canine, avian ... of various types such as Attenuated Live Vaccines, ... DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines ... or bacteria, which have been weakend under laboratory ...
(Date:4/19/2017)... 19, 2017  SARES•REGIS Group leased the first ... at Conejo Spectrum Business Park in ... Biotherapeutics, Inc. , a biopharmaceutical company developing meaningful ... that have been underserved by scientific innovation, with ... cancer, autoimmune and infectious disease. Before ...
Breaking Medicine Technology: